These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy. Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189 [TBL] [Abstract][Full Text] [Related]
5. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
7. Can we eliminate both calcineurin inhibitors and steroids? Lebranchu Y Transplant Proc; 2010 Nov; 42(9 Suppl):S25-8. PubMed ID: 21095446 [TBL] [Abstract][Full Text] [Related]
8. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781 [TBL] [Abstract][Full Text] [Related]
9. Albuminuria after renal transplantation: maintenance with sirolimus/low-dose tacrolimus vs. mycophenolate mofetil/high-dose tacrolimus. Miles CD; Skorupa JY; Sandoz JP; Rigley TH; Nielsen KJ; Stevens RB Clin Transplant; 2011; 25(6):898-904. PubMed ID: 21077952 [TBL] [Abstract][Full Text] [Related]
10. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients. Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352 [TBL] [Abstract][Full Text] [Related]
11. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation. Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187 [TBL] [Abstract][Full Text] [Related]
13. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Stegall MD; Wachs ME; Everson G; Steinberg T; Bilir B; Shrestha R; Karrer F; Kam I Transplantation; 1997 Dec; 64(12):1755-60. PubMed ID: 9422416 [TBL] [Abstract][Full Text] [Related]
14. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558 [TBL] [Abstract][Full Text] [Related]
15. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial. Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715 [TBL] [Abstract][Full Text] [Related]
16. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Gallon L; Perico N; Dimitrov BD; Winoto J; Remuzzi G; Leventhal J; Gaspari F; Kaufman D Am J Transplant; 2006 Jul; 6(7):1617-23. PubMed ID: 16827862 [TBL] [Abstract][Full Text] [Related]
17. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
18. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation. Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219 [TBL] [Abstract][Full Text] [Related]
19. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B; Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892 [TBL] [Abstract][Full Text] [Related]
20. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT; Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]